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ABSTRACT: The cardiac myofilaments consist of a highly ordered assem-
bly of proteins that collectively generate force in a calcium-dependent
manner. Defects in myofilament function and its regulation have been
implicated in various forms of acquired and inherited human heart dis-
ease. For example, during cardiac ischemia, cardiac myocyte contractile
performance is dramatically downregulated due in part to a reduced
sensitivity of the myofilaments to calcium under acidic pH conditions.
Over the last several years, the thin filament regulatory protein, troponin
I, has been identified as an important mediator of this response. Muta-
tions in troponin I and other sarcomere genes are also linked to several
distinct inherited cardiomyopathic phenotypes, including hypertrophic,
dilated, and restrictive cardiomyopathies. With the cardiac sarcomere
emerging as a central player for such a diverse array of human heart dis-
eases, genetic-based strategies that target the myofilament will likely have
broad therapeutic potential. The development of safe vector systems for
efficient gene delivery will be a critical hurdle to overcome before these
types of therapies can be successfully applied. Nonetheless, studies focus-
ing on the principles of acute genetic engineering of the sarcomere hold
value as they lay the essential foundation on which to build potential
gene-based therapies for heart disease.
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INTRODUCTION
Heart disease claims more lives in the United States each year than the next
four leading causes of death combined, accounting for one death every 35 s.1
Coronary heart disease is the most prevalent form of cardiovascular disease,
affecting 13 million Americans and claiming the lives of 40% of those who
experience a coronary ischemic event in a given year.1 Heart failure is sim-
ilarly a highly prevalent and fatal condition that affects 5 million Americans
and carries a 1-year mortality rate of 20%. These are staggering statistics, par-
ticularly in view of the considerable advances that have been made in medical,
device, and surgical therapies for heart disease in the last decade. Clearly there
is a continued need to develop novel therapies for cardiovascular diseases that
go beyond contemporary medicine. Some investigators contend that we may
have reached somewhat of a plateau with conventional treatments and predict
a shift in emphasis toward gene-based therapy.2
Designing molecular therapies that target the ischemic or failing heart re-
quires an understanding of the mechanisms that govern myocardial contractility
and relaxation under both normal and pathological conditions. Acute myocar-
dial ischemia alters key aspects of cardiac cell metabolism that, in turn, result
in impaired contractility. Prominent among these is intracellular acidification
caused by lactate formation during anaerobic glycolysis and by hydrolysis
of high-energy phosphate compounds.3 When blood flow to the myocardium
is acutely compromised, cardiac muscle intracellular pH drops precipitously
(from 7.0 to ∼6.2), directly depressing myocardial force4 (FIG. 1 A). This
FIGURE 1. Effects of acidosis on force and calcium. (A) Graphic representation of the
precipitous drop in both left ventricular pressure and pH during cardiac ischemia. Adapted
from Orchard and Kentish 1990. Am. J. Physiol. 258: C967–C981. (B) Effects of acidic pH
on force and the Ca2+ transient in adult cardiac muscle. Force declines when intracellular
pH drops, but the Ca2+ transient remains unchanged or may even increase. Thus, there is
an uncoupling of excitation and contraction. (C) Acidic pH desensitizes the myofilaments
to calcium, resulting in a marked rightward shift in the force-Ca2+ relationship.
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depression in contractility occurs despite an unchanged or even increased
intracellular Ca2+ transient, indicating a disruption of normal excitation–
contraction coupling (FIG. 1 B). The basis for this phenomenon is an uncoupling
of the response of the contractile proteins to activating calcium. This is man-
ifest in a marked rightward shift in the force-Ca2+ relationship under acidic
conditions (FIG. 1 C). In adult cardiac preparations, the pCa (-log [Ca2+]) re-
quired for 50% maximal activation falls by an average of ∼0.12 pCa units
for each 0.1 unit drop in pH.5 In contrast, the contractile function of neonatal
heart muscle is less affected than adult myocardium by acidic pH, ∼ 0.04 pCa
unit per 0.1 unit drop in pH.5–7 Developmentally regulated transitions in the
isoform expression profile for the myofilament protein troponin I (TnI) cor-
relate with shifts in the pH-mediated alteration in the force-Ca2+ relationship
noted for neonatal and adult myocardium.8 Thus, elucidation of key structural
and functional characteristics of TnI isoforms could form the basis for new
molecular therapies to improve contractile function during cardiac ischemia.
The importance of the myofilaments in regulation of cardiac function is
further underscored by elucidation of the genetic underpinnings of a broad
spectrum of cardiac muscle diseases over the past two decades. Primary in-
herited cardiomyopathies represent an increasingly recognized cause of “id-
iopathic” heart failure and are phenotypically categorized into three distinct
clinical subtypes: hypertrophic (HCM), dilated (DCM), and restrictive (RCM)
cardiomyopathies. While clinical classification of these cardiomyopathies is
based predominantly on morphologic and hemodynamic characteristics, many
structurally divergent cardiomyopathies share common genetic loci. Mutations
in genes encoding contractile, cytoskeletal, calcium cycling, and metabolic pro-
teins have been associated with a variety of cardiomyopathic phenotypes. Of
these, sarcomeric gene mutations are the most prevalent and well characterized
to date, with over 11 genes identified as causal for multiple cardiomyopathic
subtypes9 (FIG. 2). Since the anatomic and functional changes associated with
primary cardiomyopathic diseases are also observed in acquired forms of heart
failure (i.e., chronic ischemia, hypertension, diabetes, or valvular disorders),
it is likely that altered sarcomere function plays an important role in the patho-
genesis of acquired cardiomyopathies as well. Therefore, genetic or molecular
strategies that target the sarcomere would be expected to have broad therapeutic
benefit.
TnI ISOFORMS AND ACIDOSIS
TnI is the inhibitory subunit of the troponin complex that toggles between
actin (diastole) and troponin C (systole) in a Ca2+-dependent manner within
the sarcomere.10 There are two isoforms of TnI that are expressed in the heart
at different times during development. Typically, the slow skeletal troponin I
isoform (ssTnI) is expressed during the embryonic and early postnatal period.
440 ANNALS NEW YORK ACADEMY OF SCIENCES
FIGURE 2. Identification and sarcomeric localization of genetic loci harboring muta-
tions linked to inherited cardiomyopathies.
Shortly after birth, there is a transition in expression to the cardiac isoform
(cTnI) that persists throughout adult life.11,12 This TnI isoform transition cor-
relates with the shift in the force-Ca2+ relationship in response to changes
in pH.8 In the adult cTnI-expressing heart, contractility is severely depressed
during acidosis, largely due a decrease in the sensitivity of the myofilaments
to Ca2+. In contrast, the neonatal ssTnI-expressing heart demonstrates less of
a decrease in myofilament Ca2+ sensitivity in an acidic pH environment com-
pared to the adult heart, and consequently, contractile function is relatively
preserved.8 Although early studies showed a correlation between TnI isoform
expression and myofilament pH sensitivity, the direct role played by TnI iso-
forms in these developmental responses was obscured by concurrent changes
in other thin filament proteins over a similar time period.
Genetic engineering of TnI has clearly elucidated its isoform-dependent role
in pH-mediated contractile dysfunction. Replacement of cTnI with ssTnI in
adult cardiac myocytes using adenoviral-mediated gene transfer results in a
marked enhancement of myofilament Ca2+ sensitivity at acidic pH.6 These
data are supported by transgenic mouse studies in which replacement of native
cTnI with a ssTnI transgene increases papillary muscle tension development
during acidosis.13 Further studies using chimeras of cTnI and ssTnI provide
evidence that this pH sensing domain localizes to the carboxyl terminus of
cTnI.14,15 More recently, we have identified a key residue, histidine at position
132 in mouse ssTnI, that uniquely confers acidic pH resistance of the Ca2+-
activated myofilament apparatus.16 Adenoviral gene transfer of a modified
ssTnI molecule, in which alanine was substituted for histidine at position 132
(H132A), into adult cardiac myocytes converts the ssTnI to the cTnI phenotype
in terms of isometric, Ca2+-activated tension at acidic pH.16 Similarly, sub-
stituting histidine for alanine at codon 164 in cTnI (A164H) by gene transfer
results in a modest gain of Ca2+-activated tension at neutral pH, an effect that
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is accentuated at acidic pH.16 These data suggest that TnI isoform dependence
of pH sensitivity may relate to unique biochemical properties of this histidine
residue. Owing to its imidazole side chain, histidine is deprotonated and hy-
drophobic at neutral pH, and protonated and hydrophilic at acidic pH. Thus
the positive charge on histidine during intracellular acidosis could weaken in-
teractions between TnI and arginine or lysine residues in actin, or strengthen
interactions with glutamate or aspartate residues in troponin C (TnC), or both
(FIG. 3 A). Any of these possibilities would tend to favor a stronger TnI-TnC
association, and thus maintenance of contractile activation under acidic pH
conditions.
ENGINEERING THE SARCOMERE FOR THE ISCHEMIC
AND FAILING HEART
Myocardial ischemia can result in immediate and profound contractile fail-
ure, which often persists even after blood flow and intracellular pH have been
restored. Existing pharmacological therapies for heart failure associated with
ischemia are limited, often carry undesirable proarrhythmic side effects, and
increase energy demand in the already metabolically compromised heart.17,18
Therefore, a genetic-based approach focusing on the sarcomere to improve
cardiac function during ischemia could offer an attractive alternative.
Intracellular acidosis is a prominent component of cardiac ischemia and
contributes to contractile dysfunction and myocellular injury. Direct enhance-
ment of myocardial function under acidic pH conditions may be advantageous
during ischemia. Based on the cellular characterization studies in isolated my-
ocytes, the genetically engineered cardiac TnI molecule, A164H, appears to be
a promising therapeutic candidate to test in the ischemic heart. Indeed, recent
studies demonstrate a protective effect of this cTnI variant under a variety of
pathophysiological conditions in the whole heart ex vivo and in vivo.16 Trans-
genic mice were generated in which ∼80–85% of native cTnI was stoichio-
metrically replaced with cTnI A164H. Mouse hearts were retrograde perfused
with an acidic buffer in the context of an ex vivo isovolumic heart preparation.
Transgenic cTnI A164H mouse hearts were far more resistant to acidosis than
nontransgenic controls, demonstrating improved systolic and diastolic perfor-
mance. In vivo hypoxia and acute coronary ischemia studies yielded similar
results; improved cardiac contractility in cTnI A164H transgenic mice under
both conditions. We recently proposed that direct augmentation of sarcom-
eric Ca2+ activation under acidic pH conditions could account for the results
described here.
During global ischemia and subsequent reperfusion in isolated hearts,
cTnI A164H hearts demonstrated markedly improved myocardial recovery,
attributable to both better contractility and a blunting of postischemic contrac-
ture.16 In addition, transgenic replacement with cTnI A164H was associated
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FIGURE 3. Proposed biochemical and functional effects of cTnI A164H. (A) Schematic
representation of the troponin complex and its interactions based on the troponin core
crystal structure of Maeda and colleagues (TAKEDA S., A. YAMASHITA, K. MAEDA & Y.
MAEDA. 2003. Structure of the core domain of human cardiac troponin in the Ca (z+)-
saturated form. Nature 424: 35–41.). Cardiac troponin I (cTnI) A164H may stabilize the
open confirmation, through strengthened interactions with TnC or weakened interactions
with actin, or both. These effects are predicted to be greatest at acidic pH when histidine
is protonated and hydrophilic. (B) Summary of the effects of TnI A164H replacement on
cardiac function. The observed improvement in cardiac performance is most pronounced
under pathophysiological conditions.
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with a significant decrease in ventricular arrhythmias. These beneficial effects
of cTnI A164H in the postischemic heart were surprising, given that pH is
restored quite rapidly after the onset of reperfusion. Potential pH-independent
mechanisms to explain improved cardiac function during reperfusion include
better recovery of energetic substrates, or attenuation of the Ca2+ overload
state characteristic of the postischemic heart. 31P-NMR spectroscopy studies
provide evidence that cTnI A164H hearts may be operating in a more eco-
nomical manner in terms of high-energy phosphate utilization, both under
baseline conditions and during reperfusion. Furthermore, cTnI A164H hearts
demonstrated important adaptations in Ca2+ handling that may have occurred
by virtue of a reduced requirement for intracellular activating Ca2+. Collec-
tively, these changes may contribute to improving performance in cTnI A164H
transgenic hearts during ischemia–reperfusion.16
The A164H substitution in cTnI was also associated with an augmentation
in the function of failing mouse hearts after myocardial infarction. Transgenic
mice expressing cTnI A164H demonstrated improved systolic function and
an attenuated ventricular remodeling and hypertrophic response. Additionally,
adenoviral gene transfer of cTnI A164H into failing human cardiac myocytes
obtained at the time of cardiac transplantation improved contractility and relax-
ation and restored a more favorable force–frequency response. Taken together
with the above experimental results demonstrating the beneficial effects of the
cTnI A164H protein in the acute settings of acidosis, hypoxia, ischemia, and
ischemia–reperfusion, these data support the concept that genetic engineering
of the sarcomere could offer a viable strategy for treating ischemic heart dis-
ease and heart failure. Sarcomere gene-based therapy represents a promising
new approach for redressing heart disease, and could stand alone, or perhaps
complement other emerging genetic therapies targeting signaling pathways or
calcium homeostasis.19
SARCOMERE DYSFUNCTION IN INHERITED
CARDIOMYOPATHIES
HCM
HCM is the most prevalent inherited cardiovascular disorder, affecting 1 in
500 individuals.20 HCM carries an overall annual mortality rate of 1%, but
accounts for over a quarter of sudden cardiac deaths in young competitive ath-
letes.21 HCM is phenotypically heterogenous, but is generally characterized
by increased left ventricular wall thickness, primarily involving the interven-
tricular septum. Dynamic left ventricular outflow tract obstruction occurs in
30–50% of patients and can exacerbate symptoms of breathlessness and chest
pain.22 The histopathological hallmarks of HCM include myocyte disarray,
myocyte hypertrophy, and interstitial fibrosis.
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Over 400 mutations in 11 different sarcomeric genes have been identified as
causal for HCM, with mutations in -myosin heavy chain (MYH7) and myosin
binding protein C (MYBPC3) being the most prevalent.9 Sarcomere mutations
are identified in 30–70% of HCM patients, the frequency of which is highly
dependent on the characteristics of the study population and the comprehensive
nature of the genetic analysis.23–25 The remaining cases may be due to other as
yet unidentified mutations in sarcomere protein genes, or to mutations in other
nonsarcomeric genes.26 While each particular sarcomere gene mutation likely
influences the clinical phenotype, establishing genotype–phenotype correla-
tions is confounded by the vast number of mutations and phenotypic diversity
of HCM. For example, certain mutations have been associated with a partic-
ularly malignant phenotype (MYH7 R403Q and R719W), and others with a
more benign clinical course (MYH7 L908V, G256E, and V606M, and sev-
eral MYBPC3 mutations).25,27 However, these associations are derived largely
from pedigree analyses and may overestimate the correlation in more unse-
lected populations.23,24 Gene dosage does appear to influence the severity of
the HCM phenotype. Patients who are homozygous for a mutation or com-
pound heterozygous for different mutations (2–5% of the HCM population)
are diagnosed at a younger age, have more hypertrophy, and carry a poorer
prognosis than do patients with only one mutant allele.23,28 Other proposed
important influences on HCM phenotype include environmental factors and
genetic modifiers.25,29
Significant advances have been made in elucidating the molecular basis for
HCM through the use of a variety of experimental biochemical, cellular, and
animal models. Collectively, these models suggest that sarcomere gene muta-
tions act via a dominant negative mechanism resulting in a change of function
at the molecular level. Biophysical studies indicate that most HCM-linked
mutations directly heighten myofilament Ca2+ sensitivity causing increased
force production at lower [Ca2+]i. The magnitude of change in Ca2+ sensitiv-
ity results in a corresponding increase in contractility and an impairment of
relaxation in the intact cell.30 Increased myofilament Ca2+ sensitivity is the pri-
mary cause of slowed relaxation kinetics seen in the unloaded cardiomyocyte,
and likely contributes to diastolic dysfunction in the whole heart. While the
pathways leading from altered Ca2+ sensitivity to myocardial remodeling are
incompletely understood, there is evidence to support mechanisms involving
altered Ca2+ homeostasis,31,32 remodeling of the cardiac action potential,33
increased energetic demands,34,35 and activation of hypertrophy signaling
pathways.25
DCM
DCM affects fewer individuals (∼1 in 2800) than HCM, but carries a worse
prognosis with only 50% survival at 5 years after diagnosis.1 DCM is inherited
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in about 35% of cases, most commonly in an autosomal dominant fashion.25
DCM is characterized by ventricular wall thinning and dilation and impaired
contractile function. The histopathological findings are often nonspecific, re-
vealing myocyte hypertrophy, myocyte degeneration, and interstitial fibrosis.
The first identified mutations linked to DCM were in genes encoding for
cytoskeletal proteins.36 This led to the hypothesis that the pathogenesis of
DCM may be related to impaired force transmission between the contractile
apparatus, the extracellular matrix, and the sarcolemmal membrane. How-
ever, subsequent identification of mutations in genes (25 genetic loci to date)
encoding proteins with diverse functions suggested the existence of several
pathways that could independently lead to DCM. Seven of the loci linked
to DCM encode for sarcomeric proteins actin, -MHC, -MHC, titin, cTnT,
cardiac troponin C (cTnC), and -tropomyosin (Tm).9,37,38 In recent biochem-
ical studies, DCM-causing mutations in Tm, TnT, and TnC uniformly result
in decreased myofilament Ca2+ sensitivity and depressed myofibrillar func-
tion after thin filament reconstitution.39,40 These changes are quantitatively
opposite to those resulting from HCM-associated thin filament mutations,
suggesting that distinct changes in myofilament activation may account, at
least in part, for the divergent clinical phenotypes observed in DCM compared
to HCM.
RCM
RCM is the least common inherited cardiomyopathy (∼5% of all cardiomy-
opathies) but carries the worst prognosis.25 Idiopathic RCM typically presents
early in childhood and frequently results in early transplantation or sudden
cardiac death. RCM is characterized by decreased myocardial compliance and
diastolic dysfunction, but normal to near-normal systolic function and my-
ocardial wall thickness. Extensive interstitial fibrosis is a common histopatho-
logical finding.41 A recent study identified six different mutations (L144Q,
R145W, A171T, K178E, D190G, and R192H) in the cTnI gene that were
linked to both RCM and HCM phenotypes within the same families.42 Many
of these family members presented with early heart failure, and patients with
the L144Q, D190G, and R192H cTnI mutations all died of sudden cardiac
death before the fourth decade of life. The molecular basis for RCM has not
been well characterized, although biochemical studies using reconstituted con-
tractile systems from two different laboratories indicate that RCM mutations in
cTnI result in a potent increase in myofilament Ca2+ sensitivity of force genera-
tion and ATPase activity.43,44 The degree of myofilament Ca2+ hypersensitivity
resulting from these cTnI mutations is quantitatively greater than that observed
in similar previous experiments using exclusively HCM-causing cTnI muta-
tions (R145G, R145Q, R162W, K183, S199N, G203S, and K206Q). These
data suggest that the magnitude of change in myofilament Ca2+ sensitivity
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may be a stimulus for the differentiation of distinct HCM or RCM pathways.
However, the association of the same cTnI mutation with either HCM or RCM
within the same family also suggests that additional genetic or environmental
factors are important in modifying the disease phenotype.
GENETIC ENGINEERING FOR INHERITED
CARDIOMYOPATHIES
There are a number of genetic therapies for heart failure that have been tested
in a variety of animal models, most targeting components of calcium handling
or the adrenergic signaling cascade.19,45,46 Interruption of hypertrophic sig-
naling pathways has also been achieved in animal models of pressure overload
hypertrophy.47–49 Similarly directed sarcomeric-based therapies may also re-
mediate the functional and structural remodeling processes associated with
inherited cardiomyopathies. The sarcomere maintains stoichiometric propor-
tions between each protein constituent. Introduction of an exogenous gene
encoding a sarcomere protein into an individual myocyte in vitro, or into the
whole heart in vivo, results in stoichiometric replacement rather than overex-
pression of the contractile protein, such that the total amount of the targeted
protein remains unchanged.50,51 Endogenous myofilament turnover lays the
framework for the development of sarcomere gene transfer approaches for in-
herited cardiomyopathies. Exogenous expression of a wild-type allele could
in principle “compete off” a mutant allele of the same gene, thereby limiting
the effective mutant gene dosage. Alternatively, introduction of a functionally
complementary sarcomere gene allele might be able to counter the effects of a
particular mutant allele on force production or propagation. For example, “nor-
malization” of myofilament Ca2+ sensitivity might be achieved by introducing
a sarcomeric variant that heightens Ca2+sensitivity into a heart expressing a
DCM-linked sarcomere mutation associated with reduced Ca2+ sensitivity and
vice versa. These sarcomere gene-based therapeutic approaches, while theo-
retically promising, await further experimental study.
SUMMARY
The myofilaments play a central role in the regulation of cardiac function
in acquired and inherited forms of human heart disease. Contractile dysfunc-
tion during cardiac ischemia is directly attributable to an uncoupling of the
response of the contractile proteins to activating calcium. TnI is an important
mediator of this response, and expression of different TnI isoforms during
cardiac development are largely responsible for the divergent effects of acidic
pH observed in neonatal versus adult myocardium. Recent studies highlight
the importance of a single C-terminal amino acid (A164 in cTnI and H132
in ssTnI) in regulating cardiac function during acidosis, ischemia, and heart
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failure. Mutations in genes encoding a number of sarcomere proteins trigger
various forms of inherited cardiomyopathies, including hypertrophic, dilated,
and restrictive subtypes. Thus, altered sarcomere function forms the patho-
genetic basis of a broad spectrum of cardiac muscle diseases, and provides an
appealing target for gene-based therapies. The capability of the sarcomere to
incorporate exogenous proteins and maintain stoichiometric proportions would
facilitate such therapeutic approaches. Further studies focusing on sarcomere
genetic engineering in the cell and whole organ, as well as on development of
safe and efficient vector systems for gene delivery into the cardiac myocyte
in vivo, will lay the foundation for new gene-based therapies for common
acquired and inherited forms of heart disease.
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